Patients living with severe or rare diseases face many challenges, but accessing novel therapeutics through clinical research should not be one of them.
International Brain Tumour Awareness Week presented a timely opportunity to consider how the clinical trials industry navigates research into notoriously difficult-to-study indications, such as brain tumours.
For example, in recurrent glioblastoma, a type of brain tumour, registrational studies investigating new potential treatments have a high failure rate, even in cases where there has been positive early-stage data.
Check out the rest of this feature here
